Isis Pharmaceuticals’ License Agreement with Bayer for ISIS-FXI Rx Receives Hart-Scott-Rodino Approval

Isis Pharmaceuticals, Inc. (ISIS) today announced that its license agreement with Bayer HealthCare (Bayer) to develop and commercialize ISIS-FXIRx has received clearance under the Hart-Scott-Rodino Antitrust Improvements Act.  After completion of ongoing activities at Isis, Bayer will assume all global clinical development as well as worldwide regulatory and commercialization responsibilities for ISIS-FXIRx.  ISIS-FXIRx is an antisense drug in development for the prevention of clotting disorders.

Read the entire article here.

Similar Posts